Pharmacogenetic genotype and phenotype frequencies in a large Danish population-based case-cohort sample

[1]  D. Müller,et al.  Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population , 2020, Pharmacopsychiatry.

[2]  T. Werge,et al.  Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial. , 2020, JAMA network open.

[3]  Bahareh Behroozi Asl,et al.  Review and Consensus on Pharmacogenomic Testing in Psychiatry , 2020, Pharmacopsychiatry.

[4]  C. Gasse,et al.  Pharmacogenetics in psychiatric care, a call for uptake of available applications , 2020, Psychiatry Research.

[5]  M. Relling,et al.  Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group , 2019, Clinical and translational science.

[6]  M. Ingelman-Sundberg,et al.  Development of the PGx‐Passport: A Panel of Actionable Germline Genetic Variants for Pre‐Emptive Pharmacogenetic Testing , 2019, Clinical pharmacology and therapeutics.

[7]  Deepak L. Bhatt,et al.  CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta‐analysis of randomized clinical trials , 2018, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[8]  A. V. van Kuilenburg,et al.  DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. , 2018, The Lancet. Oncology.

[9]  K. Byron,et al.  An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes , 2018, Journal of Neural Transmission.

[10]  Richard M Weinshilboum,et al.  Pharmacogenomics: Precision Medicine and Drug Response , 2017, Mayo Clinic proceedings.

[11]  K. Sangkuhl,et al.  Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update , 2017, Clinical pharmacology and therapeutics.

[12]  M. Daly,et al.  The iPSYCH2012 case–cohort sample: new directions for unravelling genetic and environmental architectures of severe mental disorders , 2017, Molecular Psychiatry.

[13]  M O Karlsson,et al.  Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium , 2017, Clinical pharmacology and therapeutics.

[14]  Matthias Samwald,et al.  Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available , 2016, PloS one.

[15]  Melissa A. Basford,et al.  Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network , 2016, Clinical pharmacology and therapeutics.

[16]  M. Daly,et al.  High-Quality Exome Sequencing of Whole-Genome Amplified Neonatal Dried Blood Spot DNA , 2016, PloS one.

[17]  C. Altar,et al.  Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation , 2015, Current medical research and opinion.

[18]  Michael R. Jablonski,et al.  The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes , 2015, Applied & translational genomics.

[19]  Erica A. Bowton,et al.  Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing , 2013, Clinical pharmacology and therapeutics.

[20]  J J Swen,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants , 2013, Clinical pharmacology and therapy.

[21]  D. Geschwind,et al.  Sex differences in autism spectrum disorders. , 2013, Current opinion in neurology.

[22]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.

[23]  T. Klein,et al.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.

[24]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte , 2008, Clinical pharmacology and therapeutics.

[25]  Joseph Biederman,et al.  The worldwide prevalence of ADHD: is it an American condition? , 2003, World psychiatry : official journal of the World Psychiatric Association.

[26]  A. Lukowiak,et al.  Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility. , 2018, Journal of psychiatric research.

[27]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[28]  M Ingelman-Sundberg,et al.  Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity , 2005, The Pharmacogenomics Journal.